Global Cancer Therapeutics Market Outlook

 

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

The Global Cancer Therapeutics Market is a fast growing market that is relying heavily on new drugs. The total therapeutic market is expected to grow from $23.1 billion in 2004 to $60.6 billion in 2011. The targeted therapy segment is providing the growth of the entire market with an expected compound annual growth rate of 24.1 percent for 2004-2011.

Table of Contents

Global Cancer Therapeutics Market Outlook, Global Cancer Therapeutics Market OutlookIntroductionIntroductionDisclaimerCertificationContentsTop 15 Growth Cancer TherapeuticsMarket OverviewContentsResearch Scope and MethodologyAbreviationsSegmentationTargeted Therapy SegmentsTargeted Therapy DefinitionsSummary of FindingsMarket Drivers (1)Market Drivers (2)Challenges and Strategies (1)Challenges and Strategies (2)Challenges and Strategies (3)Challenges and Strategies (4)Challenges and Strategies (5)Total Market ForecastsContentsTotal Market ForecastsTotal Market Forecasts by Therapeutic ClassUS Forecasts by Therapeutic ClassEx US Forecasts by Therapeutic ClassCytotoxic Therapy ForecastsHormone Therapy ForecastsTargeted Therapy ForecastsGlobal Market Share AnalysisUS Market Share AnalysisEx US Market Share AnalysisNSCLCContentsDisease OverviewEpidemiology TrendsIncidenceMortalityTreatment OverviewCommon DrugsCommon RegimensTreatment DiagramRevenue ForecastsDrug DevelopmentBreast CancerContentsDisease OverviewEpidemiologyIncidenceMortalityTreatment OverviewCommon DrugsCommon RegimensHormone Treatment DiagramMetastatic Treatment DiagramRevenue ForecastsDrug DevelopmentColorectal CancerContentsDisease OverviewEpidemiologyIncidenceMortalityTreatment OverviewCommon DrugsCommon RegimensTreatment DiagramRevenue ForecastsDrug DevelopmentProstate CancerContentsDisease OverviewEpidemiologyIncidenceMortalityTreatment OverviewCommon DrugsCommon RegimensTreatment DiagramRevenue ForecastsDrug DevelopmentTop 15 Growth Therapeutic Cancer Drugs (Overview; Indications Development and Forecasts)ContentsTop 15 Growth Therapeutic Cancer DrugsRituxan/MabTheraTaxotereGleevec/GlivecEloxatinGemzarHerceptinZometaCasodexArimidexAvastinCamptosar/CamptoTemodar/TemodalXelodaFemaraErbituxRecent Filings and ApprovalsContentsRecent Filings and ApprovalsKey Late-Stage Pipeline DrugsContentsKey Late-Stage Pipeline DrugsAwardsContentsFrost & Sullivan AwardsCompany of the YearProduct Innovation of the YearProduct-Line/Pipeline Strategy of the YearEntrepreneurial Company of the Year Business Development Strategy of the YearFrost & Sullivan CapabilitiesContentsOur Capabilities IOur Capabilities IIOur Consulting ClientsGrowth ConsultingGrowth Consulting ProcessGrowth Consulting DeliverablesGrowth Partnership ServiceGrowth Partnership Services Platform




Keyword1

Keyword2

Keyword3

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.